QureTech Bio granted European patent for new class of antibacterials

The European patent approval provides protection until 2041. "It ensures strong protection for GmPcides, which is crucial in our industry" states Markus Thor, CEO of QureTech Bio.

QureTech Bio AB has been granted a patent by the European Patent Office (EPO) for GmPcides, a new class of synthetic antibacterials.

QureTech’s GmPcides represents an innovative class of small-molecule synthetic antibiotics that effectively target drug-resistant bacteria, including MRSA, with no evidence of resistance development.

The European patent approval, which provides protection until 2041, marks a significant milestone for the Umeå-based biotech company. The patent has already been approved in China and is pending in the USA, India, and Japan.

“We are pleased to receive this patent grant from the European Patent Office,” says Markus Thor, CEO of QureTech Bio.

“The patent ensures strong protection for GmPcides, which is crucial in our industry, and represents a significant step toward making our compounds available to patients in need of effective treatment for drug-resistant bacteria.”

The European Patent Office (EPO) granted the patent application titled “Ring-fused 2-pyridone compounds, methods for their preparation, and their use in the treatment and/or prevention of diseases involving Gram-positive bacteria” on February 26.